Company Spotlight: Therapixel MammoScreen 5 - AI Breast Cancer Screening Clearance

This episode unpacks the FDA 510(k) summary for Therapixel's MammoScreen 5, an AI tool cleared to assist radiologists in reading mammograms. Listeners will learn how the software categorizes and scores lesions, the specific performance metrics across different image combinations, and the notable gaps in the demographic data used for its standalone performance testing.

Key points

• MammoScreen 5 is a software-only device cleared by the FDA as a concurrent reading and reporting aid for screening mammograms.
• The AI outputs a MammoScreen Score from one to ten and classifies findings as mass/asymmetry, distortion, or calcifications.
• Clearance was based on substantial equivalence to MammoScreen 4, using standalone performance testing on 9,789 patients.
• The testing dataset contained significant demographic reporting gaps, with 9,461 patients listed as not reported for race and ethnicity.
• The software demonstrated non-inferiority across new scenarios, including supplementary views and specific combinations of current and prior imaging.
• The FDA explicitly warns that patient management decisions should not be made solely based on the software's analysis.

Source: FDA 510(k) summary K260714: MammoScreen® (5) (Therapixel) - U.S. Food and Drug Administration, 2026

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Company: Therapixel (therapixel.com) · Product: MammoScreen® (5) · FDA 510(k) K260714

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-therapixel-mammoscreen-5-ai-breast-cancer-screening-5aeaf6